Info

ZIOPHARM Oncology, Inc. (ZIOPHARM), incorporated in September 2003, is a development-stage biopharmaceutical company. The Company focuses on developing and commercializing a portfolio of in-licensed cancer drugs that address unmet medical needs. The Company is focused on licensing and developing drug candidate families that are related to cancer therapeutics on the market or in development and that can be developed in intravenous (IV) and/or oral forms of administration. As of December 31, 2007, it was in Phase I and Phase I/II studies for two product candidates known as darinaparsin (ZIO-101), palifosfamide (ZIO-201) and indibulin (ZIO-301).(Source: 10KSB)